Anti–CTLA-4 Immunotherapy Does Not Deplete FOXP3+ Regulatory T Cells (Tregs) in Human Cancers—Response

Clinical Cancer Research - United States
doi 10.1158/1078-0432.ccr-19-0402
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Association for Cancer Research (AACR)

Related search

CTLA-4 Expressed by FOXP3+ Regulatory T Cells Prevents Inflammatory Tissue Attack and Not T-Cell Priming in Arthritis

Immunology
AllergyImmunology
2017English

Anti-Regulatory T Cell Vaccines in Immunotherapy: Focusing on FoxP3 as Target

Human Vaccines and Immunotherapeutics
MedicineAllergyImmunologyPharmacology
2019English

Intestinal Microbiota Predict Response and Toxicities During Anti-Pd-1/Anti-Ctla-4 Immunotherapy

Pathology
Forensic MedicinePathology
2020English

CTLA4 Methylation Predicts Response to Anti–PD-1 and Anti–CTLA-4 Immunotherapy in Melanoma Patients

JCI insight
Medicine
2018English

DNA Methyltransferase Inhibition Promotes Th1 Polarization in Human CD4+CD25high FOXP3+ Regulatory T Cells but Does Not Affect Their Suppressive Capacity

Journal of Immunology Research
MedicineAllergyImmunology
2018English

Higher Frequencies of GARP+CTLA-4+Foxp3+ T Regulatory Cells and Myeloid-Derived Suppressor Cells in Hepatocellular Carcinoma Patients Are Associated With Impaired T-Cell Functionality

Cancer Research
Cancer ResearchOncology
2013English

Regulatory T Cells in Cancer Immunotherapy

Current Opinion in Immunology
AllergyImmunology
2014English

Regulatory T Cells in Cancer Immunotherapy

Cell Research
Cell BiologyMolecular Biology
2016English

CD90+ Human Dermal Stromal Cells Are Potent Inducers of FoxP3+ Regulatory T Cells

Journal of Investigative Dermatology
BiochemistryDermatologyCell BiologyMolecular Biology
2015English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy